This website is best viewed using the vertical display on your mobile device.

BMS Partnership

At Bristol-Myers Squibb, we work every day to advance science for patients with serious diseases. We are a company that is delivering for patients today, while discovering and developing transformational medicines for patients tomorrow.

We believe in the power of science to address some of the most challenging diseases of our time. We have a high bar for innovation, focused on areas where our medicines can truly make a difference for patients. Our focus on these unmet needs comes at an unprecedented time, where scientific breakthroughs are advancing the treatment of disease like never before.

We pioneered a class of medicines that harness the power of the immune system to treat cancer. These agents are changing the way cancer is treated, and we are just at the beginning.

We are more than a cancer company. We have a legacy of transforming patient outcomes in major diseases such as cardiovascular disease, HIV and HCV. We are pursuing medicines with transformational potential in diseases such as heart failure, liver fibrosis and rheumatoid arthritis.

As a consequence of the discovery, development and delivery of innovative medicines, there’s a clear need for a good understanding of both scientific and clinical principles.

We believe we need to drive education. We believe that in supporting the ImmunoScience Academy, driven by the Steering Committee, we create added value in the field of immunoscience and its related clinical applications to improve patient outcomes, in line with our mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.